Diagnostyka - Public Comps and Valuation Multiples

Diagnostyka Overview

About Diagnostyka

Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.

Founded

HQ

Employees

n/a

Website

diag.pl

Sectors

Medical Imaging & Diagnostics
HealthTech

Financials

LTM Revenue $624M

LTM EBITDA $161M

EV

$2.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Diagnostyka Financials

As of September 2025, Diagnostyka reported last 12-month revenue of $624M and EBITDA of $161M.

In the same period, Diagnostyka generated $499M in LTM gross profit and $70.8M in net income.

See Diagnostyka valuation multiples based on analyst estimates

Diagnostyka P&L

In the most recent fiscal year, Diagnostyka reported revenue of $530M and EBITDA of $138M.

Diagnostyka expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Diagnostyka valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$624M	XXX	$530M	XXX	XXX	XXX
Gross Profit	$499M	XXX	$345M	XXX	XXX	XXX
Gross Margin	80%	XXX	65%	XXX	XXX	XXX
EBITDA	$161M	XXX	$138M	XXX	XXX	XXX
EBITDA Margin	26%	XXX	26%	XXX	XXX	XXX
EBIT	$110M	XXX	$87.2M	XXX	XXX	XXX
EBIT Margin	18%	XXX	16%	XXX	XXX	XXX
Net Profit	$70.8M	XXX	$60.6M	XXX	XXX	XXX
Net Margin	11%	XXX	11%	XXX	XXX	XXX
Net Debt	XXX	XXX	$150M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Diagnostyka including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $624M. EBITDA for the last twelve months was $161M. In the most recent fiscal year, Diagnostyka achieved $530M in revenue and $138M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$624M	Analyst estimates available to subscribers	$530M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$499M	Analyst estimates available to subscribers	$345M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	80.1% gross margin	Analyst estimates available to subscribers	65.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$161M	Analyst estimates available to subscribers	$138M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	25.8% EBITDA margin	Analyst estimates available to subscribers	26.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$110M	Analyst estimates available to subscribers	$87.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	17.6% EBIT margin	Analyst estimates available to subscribers	16.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$70.8M	Analyst estimates available to subscribers	$60.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	11.3% net profit margin	Analyst estimates available to subscribers	11.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$150M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Diagnostyka

This financial data table provides comprehensive performance metrics for Diagnostyka, a company based in Poland. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Diagnostyka generated $624M in revenue over the last twelve months.
The company achieved $161M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $499M.
Net income over the last twelve months reached $70.8M.

Fiscal Year Performance

In the most recent fiscal year, Diagnostyka reported $530M in total revenue.
Fiscal year EBITDA was $138M.
The company maintained a gross profit margin of 65.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was 26.1%.
Net profit margin reached 11.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Diagnostyka. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Diagnostyka Stock Performance

Diagnostyka has current market cap of PLN 6.2B (or $1.7B), and EV of PLN 7.2B (or $2.0B).

Market Cap Evolution

Diagnostyka Stock Data

As of October 17, 2025, Diagnostyka's stock price is PLN 185 (or $50).

See Diagnostyka trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.0B	$1.7B	XXX	XXX	XXX	XXX	$2.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Diagnostyka Valuation Multiples

Diagnostyka's trades at 3.7x EV/Revenue multiple, and 14.2x EV/EBITDA.

See valuation multiples for Diagnostyka and 15K+ public comps

Diagnostyka Financial Valuation Multiples

As of October 17, 2025, Diagnostyka has market cap of $1.7B and EV of $2.0B.

Equity research analysts estimate Diagnostyka's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Diagnostyka has a P/E ratio of 24.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.7B	XXX	$1.7B	XXX	XXX	XXX
EV (current)	$2.0B	XXX	$2.0B	XXX	XXX	XXX
EV/Revenue	3.1x	XXX	3.7x	XXX	XXX	XXX
EV/EBITDA	12.2x	XXX	14.2x	XXX	XXX	XXX
EV/EBIT	17.9x	XXX	22.5x	XXX	XXX	XXX
EV/Gross Profit	3.9x	XXX	n/a	XXX	XXX	XXX
P/E	24.0x	XXX	28.0x	XXX	XXX	XXX
EV/FCF	n/a	XXX	25.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Diagnostyka Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Diagnostyka Margins & Growth Rates

Diagnostyka's last 12 month revenue growth is 15%

Diagnostyka's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Diagnostyka's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Diagnostyka's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Diagnostyka and other 15K+ public comps

Diagnostyka Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	15%	XXX	18%	XXX	XXX	XXX
EBITDA Margin	26%	XXX	26%	XXX	XXX	XXX
EBITDA Growth	17%	XXX	28%	XXX	XXX	XXX
Rule of 40	38%	XXX	41%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	62%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	49%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial